



CELLUMEN TO PRESENT AT BIO-IT WORLD CONFERENCE & EXPO '09

Dr. Albert Gough to participate in workshop on drug safety informatics on Monday, April 27th at 12:40pm

Pittsburgh, PA, April 22, 2009 – [Cellumen, Inc.](#), a drug discovery and early safety assessment company, today announced that [Albert Gough, Ph.D.](#), Vice President of Technology, will participate in “[Advances in Drug Safety Informatics](#),” a workshop at [Bio-IT World Conference & Expo '09](#). This workshop will be held Monday, April 27, 2009, from 12:30 p.m. – 4 p.m. in the World Trade Center, Boston, MA.

Dr. Gough’s portion of the presentation, “[Classification of Compound Safety Using Cellular Systems Biology](#)”, will begin at 12:40 p.m. Dr. Gough will address Cellumen’s Cellular Systems Biology (CSB™) panels, known as CellCiphr®, and their broad characterization of the effects of compound exposure on cellular functions, including mechanisms of toxicity. In addition, he will discuss how Cellumen has developed CSB panels, a reference database of compounds with in vivo safety data and classification methods to reduce the complexity of CSB profiles to actionable results (e.g. Hepatic Safety Alerts), and why the goal of improving the prediction of safety liabilities in animal models and humans using in vitro methods is reliable. Dr. Gough will also present the application of the use of the CellCiphr to prioritize lead series using these current panels.

“I’m looking forward to being part of a discussion on such a relevant topic in healthcare,” says Dr. Gough. “Cellumen has always made the integrated use of early safety profiling methods coupled to efficacy profiling of drug candidates a top priority. The addition of Dr. Jack A. Reynolds to our [Board of Directors](#) and the promotion of [Patricia “Kate” A. Johnston, Ph.D.](#), as Chief Scientific Officer, have strengthened our position as a leader in working at the interface between drug discovery and development.”

Additional participants in “Advances in Drug Safety Informatics” include: Alex Tropsha, Ph.D., Chair, Department of Medicinal Chemistry and Natural Products, University of North Carolina School of Pharmacy; Nigel Greene, Ph.D., Senior Principle Scientist, Toxicoinformatics, Pfizer Global R&D; David Cook, Ph.D., Associate Director, Global Safety Assessment, AstraZeneca UK; and Kelley Moore, Division of Biostatistics, School of Public Health, University of California, Berkeley.

If you are interested in this workshop, but are unable to attend, please contact Don Taylor, senior director of marketing and corporate development at don.taylor@cellumen.com for additional information.

About Cellumen

Cellumen is the leading collaborative partner and outsource service provider for the continuum of cell-based drug discovery and early safety assessment solutions. Through its [CellCiphr® CSB™ Early Safety Assessment Profiling Services](#), Cellumen can “alert” the discovery/development scientists that a compound has a high safety liability before entering pre-clinical safety testing. This allows the medicinal chemists time to explore ways to minimize the safety liability and/or to choose an alternative compound in a lead series, resulting in a reduction of drug failure rates and development costs. Leading global organizations, including top pharmaceutical companies, the EPA, FDA, and NIH, partner with Cellumen. Cellumen is a partner company of [Safeguard Scientifics](#). Other investors include Novitas Capital, the Pittsburgh Life Sciences Greenhouse and Innovation Works. For more information about Cellumen, please visit www.cellumen.com.

Cellumen Media Contact

Theresa Murray
Gregory FCA
610-642-8253 x164
Theresa@GregoryFCA.com